What does the mechanism of survodutide predict that SURPASS-3 did not test?

Conditions: survodutide · SURPASS-3.

I want to know whether this is a real physical effect or an artefact of how it is measured.

What prompted the question is an inconsistency between two sources I otherwise trust.

What is the causal chain, and where does it stop being established?

Dose equivalence across agents with different receptor profiles is not a defensible concept, and the attempt to construct it is the most common analytical error in this area.

Receptor desensitisation as a plateau mechanism is plausible and poorly evidenced. GLP-1R internalises on agonist binding and recycles, and biased agonists that internalise less have been argued to sustain signalling better. Whether any of that operates at the timescale of a four-month clinical plateau — against the much simpler explanation that energy expenditure fell with mass — is not established.

Comparing a 2.4 mg dose of one agonist to a 15 mg dose of another tells you nothing, because the molar potencies at their respective receptors differ, the receptor profiles differ, and the exposure per milligram differs. The only defensible comparison is between clinical outcomes in trials with comparable populations and durations, which is why SURMOUNT-5 exists and why indirect comparisons should be read sceptically.

The role of the area postrema and the hypothalamic arcuate nucleus in GLP-1-mediated appetite suppression is supported by both the neuroanatomy of receptor expression and by the effect of lesioning studies in animal models.

The chemistry is the interesting part and it is also the well-documented part. Read the medicinal chemistry papers; they are short and they explain the design.

The half-life is a formulation achievement rather than an intrinsic property. Native GLP-1 has a plasma half-life of a couple of minutes; everything in this class is a set of modifications engineered to defeat that.

The GIP agonism-versus-antagonism question remains open, and the awkward fact is that both directions have produced weight loss in humans. The reconciling hypothesis is that chronic GIPR agonism produces receptor desensitisation and therefore functions as a pharmacological antagonist, but that is a hypothesis fitted to the data rather than an independent finding.

Concretely, orforglipron is not a peptide at all, which changes everything downstream: it is orally bioavailable without an absorption enhancer, it has no fasting or water requirement of the same kind, it does not require cold chain, and it cannot be assayed by any of the peptide methods discussed elsewhere on this site.

One qualification: none of the investigational agents discussed here is approved anywhere, and material supplied for research use is not approved for human use.

Structure predicts pharmacokinetics reliably and clinical effect unreliably. Keep the two claims separate.

edited 30 Jan 2025 by gradient_slope — reworded for clarity after a comment

GLP-1R is a class B G-protein-coupled receptor signalling predominantly through Gs and cyclic AMP, and most of the interesting pharmacology in this class is about where that signalling happens rather than how hard it is driven.

What the glucagon arm of a tri-agonist adds is energy expenditure and hepatic fat mobilisation; what it costs is glycaemic control and an increase in heart rate. That is why the tri-agonists show a steeper weight-loss curve and why their development requires more care around cardiac and glycaemic endpoints than a pure GLP-1 agonist does.

Oral semaglutide’s absorption mechanism via SNAC is described in the pharmacokinetic literature, and the ~1 per cent bioavailability figure with high inter- and intra-individual variability is why administration conditions are specified so tightly[1].

I would separate what is established structurally from what is inferred clinically. The chemistry is settled; the attribution of clinical effect to specific receptor arms mostly is not.

If you want to reason about a new agent, start from its receptor profile and its half-life. Almost everything else follows.

Two structural interventions do the work: substitution at the DPP-4 cleavage site to stop enzymatic degradation, and a fatty-acid chain to bind serum albumin and create a slowly released reservoir. Remove either and you are back to a compound requiring continuous infusion.

Amylin co-agonism adds to a GLP-1 effect rather than duplicating it because the two act through different circuits: amylin signals through the area postrema via calcitonin receptor complexes, GLP-1 through both the area postrema and the arcuate nucleus. Two non-redundant satiety signals summate, which is the design rationale for a co-formulation rather than a higher dose of either.

Worth noting that receptor pharmacology measured in a transfected cell line is a starting point, not a physiological measurement, and potency ratios do not transfer cleanly in vivo.

Do not convert doses between agents. There is no exchange rate, and constructing one is how people arrive at an order-of-magnitude error.

edited 28 Feb 2025 by mz_4113 — added a caveat about sampling